(NASDAQ: IRWD) Ironwood Pharmaceuticals's forecast annual revenue growth rate of 23.58% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.52%, and it is also forecast to beat the US market's average forecast revenue growth rate of 12.17%.
Ironwood Pharmaceuticals's revenue in 2026 is $400,296,000.On average, 6 Wall Street analysts forecast IRWD's revenue for 2026 to be $83,348,185,630, with the lowest IRWD revenue forecast at $79,351,790,283, and the highest IRWD revenue forecast at $86,531,726,744. On average, 6 Wall Street analysts forecast IRWD's revenue for 2027 to be $87,035,001,055, with the lowest IRWD revenue forecast at $82,255,550,614, and the highest IRWD revenue forecast at $92,233,294,919.
In 2028, IRWD is forecast to generate $133,332,926,596 in revenue, with the lowest revenue forecast at $84,202,427,551 and the highest revenue forecast at $229,950,005,640.